Superworth

CNS Pharmaceuticals EPS CNSP

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
−$0.38
Fiscal year 2023
−$173100.00

CNS Pharmaceuticals' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$0.38.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2023−$173100.00n/a
FY2022−$334200.00n/a
FY2021−$486000.00n/a
FY2020−$513000.00n/a
FY2019−$243000.00n/a
FY2018n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.38n/an/a
Q1 FY26−$7.30n/an/a
Q3 FY25−$5.76n/an/a
Q2 FY25−$6.42n/an/a
Q1 FY25−$18.93n/an/a
Q3 FY24−$153.20n/a−$48248.16
Q2 FY24−$4049.20n/a−$80578.96
Q1 FY24−$12245.76n/a−$107645.76
Q4 FY23−$31800.00n/a−$173100.00
Q3 FY23−$32484.00n/a−$245400.00
Q2 FY23−$31116.00n/a−$289716.00
Q1 FY23−$77700.00n/a−$338700.00

Against its peers

Companies in Healthcare nearest CNS Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
CNSPCNS Pharmaceuticalsn/m
NEPHNephros$0.16+33% a year
ATNMActinium Pharmaceuticals$0.36
APTAlpha Pro Tech$0.41+24% a year
SPROSpero Therapeutics$0.11
Peer median$0.26

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on CNS Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.